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Secondary Release of Exosomes From Astrocytes Contributes to the Increase
in Neural Plasticity and Improvement of Functional Recovery After Stroke
in Rats Treated With Exosomes Harvested From MicroRNA 133bOverexpressing Multipotent Mesenchymal Stromal Cells
Hongqi Xin,* Fengjie Wang,* Yanfeng Li,* Qing-e Lu,* Wing Lee Cheung,† Yi Zhang,*
Zheng Gang Zhang,* and Michael Chopp*‡
*Department of Neurology, Henry Ford Hospital, Detroit, MI, USA
†Department of Emergency Medicine, Henry Ford Hospital, Detroit, MI, USA
‡Department of Physics, Oakland University, Rochester, MI, USA

We previously demonstrated that multipotent mesenchymal stromal cells (MSCs) that overexpress microRNA
133b (miR-133b) significantly improve functional recovery in rats subjected to middle cerebral artery occlusion
(MCAO) compared with naive MSCs and that exosomes generated from naive MSCs mediate the therapeutic benefits of MSC therapy for stroke. Here we investigated whether exosomes isolated from miR-133boverexpressing MSCs (Ex-miR-133b+) exert amplified therapeutic effects. Rats subjected to 2 h of MCAO
were intra-arterially injected with Ex-miR-133b+, exosomes from MSCs infected by blank vector (Ex-Con), or
phosphate-buffered saline (PBS) and were sacrificed 28 days after MCAO. Compared with the PBS treatment,
both exosome treatment groups exhibited significant improvement of functional recovery. Ex-miR-133b+ treatment significantly increased functional improvement and neurite remodeling/brain plasticity in the ischemic
boundary area compared with the Ex-Con treatment. Treatment with Ex-miR-133b+ also significantly increased
brain exosome content compared with Ex-Con treatment. To elucidate mechanisms underlying the enhanced
therapeutic effects of Ex-miR-133b+, astrocytes cultured under oxygen- and glucose-deprived (OGD) conditions were incubated with exosomes harvested from naive MSCs (Ex-Naive), miR-133b downregulated MSCs
(Ex-miR-133b−), and Ex-miR-133b+. Compared with the Ex-Naive treatment, Ex-miR-133b+ significantly
increased exosomes released by OGD astrocytes, whereas Ex-miR-133b− significantly decreased the release.
Also, exosomes harvested from OGD astrocytes treated with Ex-miR-133b+ significantly increased neurite
branching and elongation of cultured cortical embryonic rat neurons compared with the exosomes from OGD
astrocytes subjected to Ex-Con. Our data suggest that exosomes harvested from miR-133b-overexpressing
MSCs improve neural plasticity and functional recovery after stroke with a contribution from a stimulated
secondary release of neurite-promoting exosomes from astrocytes.
Key words: MicroRNA 133b (miR-133b); Exosome; Multipotent mesenchymal stromal cell (MSCs);
Neural plasticity; Astrocyte; Stroke; Functional recovery

INTRODUCTION
Multipotent mesenchymal stromal cells (MSCs)
enhance functional recovery in experimental stroke models
by amplifying neurogenesis, angiogenesis, and neural
plasticity1–5. Our prior in vitro and in vivo studies indicated that the therapeutic benefits of MSC-based therapies
are mediated by exosome-enriched extracellular particles
that transfer microRNAs (miRNAs) from MSCs to neural
cells6–10. This exosome transfer of miRNAs evokes neurite
remodeling and brain plasticity and subsequently benefits

functional recovery6,8. Treatment of rats subjected to middle cerebral artery occlusion (MCAO) with MSCs overexpressing microRNA 133b (miR-133b) augments neurite
remodeling and brain plasticity and subsequently improves
functional recovery6. Whether treatment of stroke with cellfree exosomes enriched with miR-133b affects brain plasticity and neurological recovery has not been investigated.
Exosomal release is regulated by specific physiological and pathological conditions11–13 and by multivesicular
body (MVB) fusion with the plasma membrane. Factors
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that impact MVB fusion affect exosome secretion, for
example, intracellular calcium14–16, K+-induced depolarization15, and glutaminergic activity17. Extracellular exosomes may also impact the exosomes released by the
recipient cells. An in vitro study has shown that exosomes
from normal human mammary epithelial cells inhibit
exosome secretion from breast cancer cells by means of
negative feedback control after intake of the epithelial
cell exosomes by breast cancer cells18.
Here we intra-arterially (IA) administered miR-133benriched exosomes derived from MSCs to rats subjected
to MCAO and investigated whether these exosomes exert
amplified therapeutic effects compared with the control
MSC exosomes. We demonstrated that exosomes tailored
with enriched miR-133b from MSCs enhance neurological
recovery and plasticity poststroke compared with the control MSC exosomes. We further demonstrated, for the first
time, using in vivo and in vitro approaches, that miR-133benriched exosomes amplify neurite outgrowth poststroke
by stimulating secondary release of astrocytic exosomes.
MATERIALS AND METHODS
All experimental procedures were carried out in
accordance with the National Institutes of Health (NIH)
Guide for the Care and Use of Laboratory Animals and
were approved by the Institutional Animal Care and Use
Committee (IACUC) of the Henry Ford Health System.
All exosome-enriched extracellular vesicles (EVs) were
collected using multistep ultracentrifugation, and their
sizes were verified by transmission electron microscopy
as well as Western blot detection of common exosomal
proteins, CD6319,20 and CD8121,22. For simplification, in
the present study, we refer to these EVs as exosomes.
Production for miR-133b Knockin or Knockdown
MSC Exosomes
MSCs (three to four passages (P3~4)] were dissociated from Wistar rat bone marrow, cultured, and then
infected with lentivirus, as previously described6,23–25. The
lentivirus was constructed with the vectors of LentimiRaGFP-hsa-miR-133b Vector (mh10170; pre-miR-133b
was inserted for miR-133b knockin, Lenti-miR-133b+;
Applied Biological Materials Inc., Richmond, Canada),
pLenti-III-miR-GFP Control Vector (m001; vector for
miR-133b knockin control, Lenti-miR-CON+; Applied
Biological Materials Inc.), miRZip-133b anti-miR-133b
miRNA construct (MZIP133b-PA-1; miR-133b inhibitor inserted for miR-133b knockdown, Lenti-miR133b−; System Biosciences, LLC, Palo Alto, CA, USA),
and pGreenPuro Scramble Hairpin Control Construct (MZIP000-PA-1; vector for miR-133b knockdown control, Lenti-miR-CON−; System Biosciences,
Inc.), respectively, according to the manufacturer’s
suggested protocol. MSCs were infected with lentivirus
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when they achieved 80%–90% confluence and were
selected by puromycin for constant gene expression.
Correspondingly, the MSCs generated are referred to as
miR-133b+MSCs, miR-CON+MSCs, miR-133b−MSCs, and
miR-CON−MSCs, respectively. For the harvesting of exosomes, we replaced conventional culture medium with an
exosome-depleted fetal bovine serum (FBS; EXO-FBS250A-1; System Biosciences, Inc.) medium when the cells
reached 60%–80% confluence. After an additional 24 h of
culturing, the media were then collected and centrifuged
at 3,000 ´ g for 30 min to remove the dead cells and large
cell apoptotic bodies; then the upper media were stored in
a −80°C freezer for exosome isolation.
MCAO Model, Exosome Treatment,
and Behavioral Tests
In our previous in vivo stroke studies, we administered
exosomes intravenously7. In addition, we have shown that
direct application of MSC exosomes on cultured cortical
neurons induces neurite outgrowth via transfer of miR133b8. In the current study, in order to reduce the potential liver and lung sequestration of exosomes26,27 and to
optimize the MSC exosome localization with neural
parenchymal cells, we administered the exosomes using
an IA approach.
Adult male Wistar rats (weighing 270–300 g) were
purchased from Charles River Laboratories (Wilmington,
MA, USA) and were subjected to 2 h of MCAO using
a method of intraluminal vascular occlusion as modified in our laboratory28,29. Briefly, rats were anesthetized
with 3.5% isoflurane for induction and maintained by
spontaneously respired 1.0% isoflurane in a 2:1 N2O/O2
mixture using a face mask. The rectal temperature was
kept at 37 ± 1°C throughout the surgical procedure using
a feedback-regulated water-heating system. MCAO was
induced by advancing a 4-0 surgical nylon suture, with
its tip rounded by heating near a flame, from the external
carotid artery into the lumen of the internal carotid artery
(ICA) to block the origin of the right middle cerebral
artery (MCA). After 2 h of MCAO, animals were reanesthetized with isoflurane, and reperfusion was performed
by withdrawal of the suture until the tip cleared the lumen
of the external carotid artery. The procedure provides a
focal infarct in the unilateral striatum and cortex28,30.
Twenty-four hours after induction of stroke, rats were
randomly administered exosomes (3 ´ 1011 particles, comparable to 100 µg of total exosome protein, per rat)
harvested from miR-CON+MSCs (Ex-Con) or from miR133b+MSCs (Ex-miR-133b+) dissolved into 0.5 ml of
phosphate-buffered saline (PBS; Thermo Fisher Scientific
Inc., Grand Island, NY, USA) or 0.5 ml of PBS as vehicle
control (n = 6/group).
For evaluation of functional recovery, a foot fault test31
and a modified neurologic severity score (mNSS) test32
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were performed prior to MCAO and 1, 3, 7, 14, 21, and
28 days after MCAO by an investigator blinded to the
treatments. All rats were sacrificed 28 days after MCAO.
Rat brains were snap frozen in liquid nitrogen, and the
frozen coronal sections were cut (40-µm thickness for
molecular studies, e.g., Western blot and exosome extraction; 8-µm thickness for immunohistochemical staining)
and stored in −80°C for subsequent analysis.
Exosome Isolation and Quantification
Exosome isolation from the cell cultured media was
performed at 4°C via multistep centrifugation, as previously described7,8,33. Briefly, the stocked cultured cell
media were thawed and followed by vortex mixing for
1 min before centrifugation, and then centrifuged at
10,000 ´ g for 30 min to remove large debris. The supernatants were filtered through a 0.22-µm filter (SLMP025SS;
EMD Millipore Corporation, Billerica, MA, USA) to
remove small cell debris, and the resulting media were
further centrifuged at 100,000 ´ g for 2 h. By this step,
the pellets primarily contained exosomes33. The final exosome pellets harvested from 1 ´ 107 cells were identified,
as previously described8, and resuspended in 30 to 50 µl
of PBS and stored at −80°C for further use.
Exosomes in the ischemic boundary zone (IBZ) were
extracted by following a previously described protocol
with modification34. Briefly, the IBZ tissues from frozen
rat brain sections were collected and digested with 20 U/
ml papain (LS 03126; Worthington Biochemical Corp.,
Lakewood, NJ, USA) in Hibernate E solution (20 µl/
mg brain tissue; Life Technologies Corporation, Grand
Island, NY, USA) for 15 min at 37°C. The brain tissue was
gently homogenized in two volumes of cold Hibernate
E solution. The brain homogenate was sequentially filtered through a Falcon™ 40-µm mesh filter (Catalog No.
08-771-1; Thermo Fisher Scientific, Hampton, NH, USA).
Exosomes were isolated from the filtrate, as previously
described15. Briefly, the filtrate was sequentially centrifuged at 300 ´ g for 10 min at 4°C, 2,000 ´ g for 10 min
at 4°C, 10,000 ´ g for 30 min at 4°C and filtered through
0.2-µm syringe filters to discard cells, membranes, and
debris. The supernatant was centrifuged at 100,000 ´ g for
2 h at 4°C to pellet exosomes. The exosome pellet was
resuspended in cold PBS, and the exosome solution was
centrifuged at 100,000 ´ g for 2 h at 4°C.
Exosomes were identified by the marker protein
CD6319,20 or CD8121,22 using Western blot, as well as
by transmission electron microscopy (TEM) to verify
the exosome size35,36. We quantitated the exosomes by
measuring the total protein concentration, assessed by
the micro bicinchoninic acid (BCA) protocol (Pierce,
Rockford, IL, USA)37 and by a qNano particle analyzer
(Izon Science Ltd., Cambridge, MA, USA) for exosome
particle number.
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In Vitro Primary Astrocyte Culture and Treatments
Extracts from cortices of embryonic day 18 Wistar rats
(either sex; Charles River Laboratories) were dissociated
into a cell suspension using mechanical digestion. After
digestion, cells were plated in 75-cm2 tissue culture flasks
at a concentration of 1.5 ´ 107 cells in Dulbecco’s modified
Eagle’s medium (DMEM; Catalog No. 11995-065; Thermo
Fisher Scientific) containing 20% FBS. The flasks were
incubated at 37°C in a moist 5% CO2, 95% air atmosphere
for 48–72 h before moving. The medium was changed
every 48–72 h. After incubating the primary cultures for
7–9 days, the flasks were placed on a shaker platform in
a horizontal position with the medium covering the cells
and were shaken at 350 rpm for 6 h at 35°C to separate oligodendrocytes from the astrocytes. Medium was changed
and flasks were placed on the shaker for an additional 18 h.
Afterward, medium was again changed and shook for an
additional 24 h. When confluent, cells were passed and used
for MSC exosome treatment. To mimic the in vivo ischemic
condition, an in vitro oxygen- and glucose-deprived (OGD)
culture system on astrocytes was employed, as previously
described38. Primary cultured astrocytes were washed twice
with PBS before MSC exosome treatment, and then the
media containing exosomes (3 ´ 1010 particles/ml) or media
alone were added to the cultured cells.
Neurite Outgrowth Assay
Primary cultures of cortical neurons were harvested
from embryonic day 18 Wistar rats, as previously
described39: Pregnant rats purchased from Charles River
Laboratories were euthanized under deep pentobarbital anesthesia. Embryos were removed, and the cerebral
cortex was dissected out, washed in Hank’s balanced salt
solution (HBSS; Gibco, Grand Island, NY, USA), and
dissociated by a combination of 0.125% trypsin digestion
for 15 min, then mechanically triturated 20 times. The
triturated cells were passed through a 40-µm cell strainer
and counted to obtain a concentration of 3 ´ 107 cells/ml.
For the neurite outgrowth assay, the neurons were then
plated overnight onto a poly(D-lysine)-coated 24-well
plate at a density of 5,000 cells per well in DMEM containing 5% FBS and antibiotics. After 24 h, cells were
washed three times with PBS and treated with various
astrocytic-derived exosomes dissolved at a concentration
of 3 ´ 1010 particles/ml into the serum-free neurobasal
medium (Gibco) supplemented with 2% B-27 (Gibco),
500 µM L-glutamine, and antibiotics (Catalog No. G6784;
Sigma-Aldrich, St. Louis, MO, USA). After 3 days, neurons were washed and fixed with 4% paraformaldehyde
(PFA) and immunofluorescence staining for b-III-tubulin (TuJ1) for neurite outgrowth analysis, as previously
described39. Briefly, to analyze neurite outgrowth, TuJ1+
cells were digitized using a 20´ objective (Carl Zeiss
Microscopy, LLC, Thornwood, NY, USA) via the Micro
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Computer Imaging Device (MCID) analysis system
(Imaging Research, St. Catharines, Canada). Neurite outgrowth was quantified using a software program developed in our laboratory that includes measurements of the
number and length of branches40. At least 50 TuJ1+ cells,
distributed in nine random fields per well, and triple wells
per group were measured, and three independent experiments were performed. All measurements were performed
by experimenters blinded to each culture condition.
miRNA Assay
For the measurement of miR-133b in exosomes from
cultured cells, samples were lysed in QIAzol reagents,
and the total RNA was isolated using the miRNeasy Mini
Kit (Qiagen, Valencia, CA, USA). By real-time polymerase chain reaction (RT-PCR), we detected the miR133b level. Briefly, miRNAs were reverse transcribed
with the miRNA Reverse Transcription Kit (Applied
Biosystems, Foster City, CA, USA), and PCR amplification was performed with the TaqMan miRNA Assay Kit
(which is specific for mature miRNA sequences; Applied
Biosystems) according to the manufacturer’s protocols,
with U6 snRNA as an internal control.
Histopathology and Immunohistochemistry
To determine neurite remodeling in the IBZ, adjacent
frozen coronal sections of rat brains were used for staining the following markers, and positive staining within the
IBZ was measured under light microscopy. Bielschowsky
silver (silver nitrate; stains neuronal processes41; SigmaAldrich) combined with Luxol fast blue (stains myelin
sheath42; Sigma-Aldrich) histochemistry staining as well
as immunostaining with antibodies against the phosphorylated epitope of neurofilament heavy polypeptide (NF-H),
clone SMI 31 (SMI 31; reacts broadly with thick and thin
axons and some dendrites43), and synaptophysin (a marker
for synapses, since synaptophysin is ubiquitously present
at the synapses44) were employed, respectively. Briefly,
for immunostaining, adjacent frozen brain sections were
incubated with the primary antibodies against SMI 31
(1:500; ab82259; Abcam, Cambridge, MA, USA), synaptophysin (1:100; MAB5258; Chemicon, Billerica, MA,
USA), and BrdU (1:100; Roche Diagnostics Corporation,
Indianapolis, IN, USA), followed with corresponding
horseradish peroxidase (HRP)-conjugated secondary
antibodies (Abcam) and 3,3¢-diaminobenzidine (DAB;
Sigma-Aldrich) developing, respectively. Positive staining within nine areas (four from the cortex, four from
the striatum, and one from the corpus callosum) selected
along the IBZ in these groups were digitized under a 40´
objective (BX40; Olympus Optical, Waltham, MA, USA)
using a 3-CCD color video camera (DXC-970MD; Sony,
Teaneck, NJ, USA) interfaced with the MCID™ software45. For the analysis of neurite remodeling, based on
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evaluation of an average of three histology slides (8-µm
thick, interval of every 10th slide) from the standard block
of each animal, the percentage of positive staining area to
the whole area of each image taken within the IBZ was
analyzed using the MCID™ software.
To detect astrocytic expression of Rab9 effector protein with kelch motifs (RABEPK) in the IBZ, double
immunofluorescence staining was employed to identify the cellular colocalization of RABEPK (1:100;
sc-107078; Santa Cruz Biotechnology, Dallas, TX, USA)
with glial fibrillary acidic protein (GFAP; a marker of
reactive astrocyte; 1:10,000; Z0334; Dako, Carpinteria,
CA, USA), followed by their corresponding second antibody staining [fluorescein isothiocyanate (FITC) labeled
for RABEPK and Cy3 labeled for GFAP].
Statistical Analysis
Data are summarized and presented using mean ±
standard error (SE). Post hoc tests were used for subgroup analysis following analysis of variance (ANOVA).
The Global test using the generalized estimating equation (GEE) was employed to evaluate the MSC exosome
treatment effects influenced by miR-133b enrichment on
functional recovery46,47. Repeated-measures analysis was
used to evaluate data with repeated measurements over
time (e.g., functional tests) or histological evaluation on
multiple regions per subject. Analysis began testing for
the factor interaction, followed by testing the main factor
effect if no interaction was detected at the 0.05 level, and/
or a subgroup analysis was performed if the interaction or
main effect was detected at the 0.05 level48. All statistical
analyses were conducted using the SAS software (version
9.2; SAS Institute, Cary, NC, USA).
RESULTS
miR-133b Level Modified by Lentivirus Introduction
of Pre-miR-133b and miR-133b Inhibitors
Quantitative RT-PCR analysis showed that mature
miR-133b levels in the MSCs infected by lentivirus carrying pre-miR-133b were increased and, concomitantly,
miR-133b levels in exosomes harvested from these MSCs
significantly increased (Table 1). Correspondingly, the
miR-133b levels in MSCs and harvested exosomes were
significantly decreased by introducing an miR-133b inhibitor into MSCs (Table 1). There was no statistical difference in miR-133b levels among naive MSCs and MSCs
infected by blank vector controls (miR-CON+MSCs and
miR-CON−MSCs) as well as in their corresponding exosomes (Table 1).
miR-133b-Enriched Exosomes Improve Neurological
Outcome After MCAO
Tailored exosomes enriched with miR-133b as well
as the exosomes harvested from blank vector control
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Table 1. Relative miR-133b Level in the Various LentivirusInfected MSCs and Their Corresponding Exosomes
Groups

In Cells
(Relative Fold)

In Exosomes
(Relative Fold)

Naive MSCs
miR-CON+MSCs
miR-133b+MSCs
miR-CON−MSCs
miR-133b−MSCs

1.0
1.01 ± 0.21
432.65 ± 125.01*
1.02 ± 0.13
0.23 ± 0.19†

1.0
0.98 ± 0.23
8.83 ± 2.31*
1.01 ± 0.34
0.45 ± 0.11†

*p < 0.01 compared with the miR-CON+MSCs; †p < 0.05 compared with
the miR-CON−MSCs.

MSCs administered IA to rats subjected to 2 h of transient MCAO significantly reduced neurological deficits
compared with the PBS-treated rats. Foot fault and mNSS
tests were performed to assess the sensorimotor function.
All rats exhibited severe sensorimotor deficit at postoperative day 1, followed by gradual improvement within
the 4-week experimental course. Compared with the PBS
treatment, both exosome treatment groups exhibited significant improvement of functional recovery in the foot
fault test (Fig. 1A) and mNSS (Fig. 1B); however, significant improvement was detected at 7 and 14 days after
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MCAO in the Ex-miR-133b+ and the Ex-Con treatment
groups, respectively. Compared with the Ex-Con, the
Ex-miR-133b+ treatment significantly increased functional improvement (p < 0.05 after day 21, respectively)
(Fig. 1A and B).
miR-133b-Enriched Exosomes Enhance Neurite
Remodeling in the IBZ
Stroke evokes partial damage and disorganization to
axon–myelin bundles in the IBZ49. Double staining for
Bielschowsky silver and Luxol fast blue was employed
to identify axons and myelin in the white matter in the
brain, respectively. Axonal density along the IBZ was
significantly increased by the exosome treatment compared with the PBS control 28 days after MCAO, and
Ex-miR-133b+ further increased the axonal density compared with the Ex-Con (p < 0.05, respectively) (Fig. 2,
row A).
The phosphorylation of the neurofilament (NF) is
considered an important determinant of filament caliber,
plasticity, and stability50. Immunocytochemically purified anti-NF-H phosphorylated antibody (clone SMI 31)
reacts broadly with thick and thin axons and some dendrites such as basket cell dendrites, but not Purkinje cell

Figure 1. MicroRNA 133b (miR-133b)-enriched exosome treatment enhances neurological outcome improvement. Foot fault test
(A) and modified neurologic severity score (mNSS) (B) data show that compared with the phosphate-buffered saline (PBS) treatment,
both multipotent mesenchymal stromal cell (MSC) exosome treatment groups exhibited significant improvement of functional recovery (p < 0.05 after day 14, respectively). Compared with the MSCs infected with blank vector (Ex-Con), exosomes isolated from miR133b-overexpressing MSCs (Ex-miR-133b+) significantly increased functional improvement (p < 0.05 after day 21, respectively). PBS,
middle cerebral artery occlusion (MCAO) rats treated with PBS; CON+, MCAO rats treated with Ex-Con; 133b+, MCAO rats treated
with Ex-miR-133b+; EXO, exosomes given. *p < 0.05, compared to PBS; #p < 0.05 compared to CON+, respectively. Mean ± standard
error (SE), n = 6/group.

Figure 2. MicroRNA 133b (miR-133b)-enriched exosomes further increase neurite remodeling and synaptic plasticity in the ischemic boundary zone (IBZ) compared to control
multipotent mesenchymal stromal cell (MSC) exosomes. Bielschowsky silver and Luxol fast blue double staining (A row), SMI 31 immunostaining (B row), and synaptophysin
immunostaining (C row) show that based on the increase of neurite remodeling and synaptic plasticity in the IBZ by the MSCs infected with blank vector (Ex-Con) treatment, the
exosomes isolated from miR-133b-overexpressing MSC (Ex-miR-133b+) treatment further increased neurite remodeling and synaptic plasticity in the IBZ. PBS, middle cerebral
artery occlusion (MCAO) rats treated with phosphate-buffered saline (PBS); CON+, MCAO rats treated with Ex-Con; 133b+, MCAO rats treated with Ex-miR-133b+. *p < 0.05,
compared to PBS; #p < 0.05 compared to CON+, respectively. Mean ± standard error (SE), n = 6/group. Scale bars: 100 µm.
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dendrites, and immunohistochemistry staining with this
antibody reveals the accumulation of phosphorylated
NF-H (p-NFH) in axons and dendrites in the peri-infarct
region after stroke51. Our data showed that the exosome
treatment significantly increased the p-NFH immunoreactive area in the IBZ compared with the PBS control
28 days after MCAO, and similarly, Ex-miR-133b+ further increased the p-NFH immunoreactivity compared
with the Ex-Con (p < 0.05, respectively) (Fig. 2, row B).
Immunostaining data also showed that compared with
the PBS control, the MSC exosome treatment significantly
increased synaptophysin, a presynaptic vesicle protein that
identifies synaptic plasticity and synaptogenesis52 in the
IBZ 28 days after MCAO, while Ex-miR-133b+ further
increased the synaptophysin immunoreactivity compared
with the Ex-Con (p < 0.05, respectively) (Fig. 2, row C).
miR-133b-Enriched Exosomes Increase Exosomes
in Ischemic Brain
Cellular release of vesicles containing functional components (e.g., RNAs and proteins) that are taken up and
incorporated into the target recipient cell has emerged
as a regulatory mechanism for coordination of nervous
system function53–55. Exosomes released by astrocytes
and other glial cells in the central nervous system (CNS)
likely modulate neuron–glial–vascular communication
and support neural plasticity33,56–58. We therefore measured the amount of exosomes present in the IBZ. Our
data show that the Ex-miR-133b+ treatment significantly
increased the presence of exosomes in brain IBZ compared with the Ex-Con treatment (p < 0.05) (Fig. 3C) and
the PBS treatment.
miR-133b-Enriched Exosomes Increase the Release
of Exosomes From Cultured Primary Astrocytes
Since astrocytes are the most abundant cells in the
nervous system and play an active role in brain recovery59–61, and OGD culture has been used as an in vitro
model to mimic the in vivo ischemic condition62–64, we
employed OGD-cultured astrocytes to elucidate mechanisms underlying the enhanced therapeutic effects of
Ex-miR-133b+ on rats subjected to MCAO. First, we
investigated the effects of Ex-miR-133b+ on astrocyte
exosomal release. OGD astrocytes were incubated with
Ex-Naive, Ex-miR-133b−, and Ex-miR-133b+, as well as
exosomes from miR-CON+MSCs and miR-CON−MSCs,
and the release of exosomes from astrocytes was quantified. Our data showed that astrocytes subjected to OGD
increased exosomal release, while MSC exosomes further
significantly increased exosomes released by OGD astrocytes. There was no statistically significant difference of
exosomes released by OGD astrocytes among the naive
MSC exosomes and the two control MSC exosome treatments (Fig. 4A). However, compared with the Ex-Naive
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Figure 3. MicroRNA 133b (miR-133b)-enriched exosomes
increased exosomes in brain ischemic boundary zone (IBZ).
Western blot shows that the common exosomal proteins CD63
and CD81 are present in the exosome extraction from the IBZ
(A). The transmission electron microscopic (TEM) images show
the morphology of exosomes presented in the brain extracellular (B), within a size range of 30–100 nm. qNano quantification data show that compared to the multipotent mesenchymal
stromal cells (MSCs) infected with blank vector (Ex-Con) treatment and phosphate-buffered saline (PBS) control, the extracellular exosomes present in the IBZ significantly increased after
miR-133b-overexpressing MSC (Ex-miR-133b+) treatment (C).
PBS, middle cerebral artery occlusion (MCAO) rats treated with
PBS; CON+, MCAO rats treated with Ex-Con; 133b+, MCAO
rats treated with Ex-miR-133b+. *p < 0.05, compared to Ex-Con.
Mean ± standard error (SE), n = 6/group. Scale bar: 100 nm.

treatment, Ex-miR-133b+ significantly increased exosomes released by OGD astrocytes (p < 0.05) (Fig. 4A),
whereas incubation of OGD astrocytes with Ex-miR133b− significantly decreased the OGD astrocytes to
release exosomes (p < 0.05) (Fig. 4B). In a complementary experiment, we also investigated the effect of overexpression of miR-133b on MSCs to release exosomes.
Infection of MSCs with the blank vector controls did not
significantly affect MSCs to release exosomes compared
to naive MSCs. However, overexpression or inhibition of
miR-133b significantly increased or decreased, respectively, MSC release of exosomes compared to naive
MSCs (p < 0.05) (Fig. 4B).
Exosomes Harvested From OGD Astrocytes Treated
With Ex-miR-133b+ Increase Neurite Outgrowth
By employing the primary cortical neuronal neurite
outgrowth assay, we tested the effects of OGD astrocyte exosomes on neurite branching and elongation of
the neurons. Our data show that exosomes harvested
from OGD astrocytes significantly increased the neurite
branch number and total neurite length per neuron compared with the non-exosome-treated neurons. Compared
to exosomes from astrocytes subjected to OGD only,
exosomes harvested from OGD astrocytes pretreated
by Ex-Con and Ex-miR-133b+ substantially increased
the neurite branch number and total neurite length of
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primary cultured cortical neurons, while exosomes from
OGD astrocytes treated by Ex-miR-133b+ employed to
treat primary cortical neurons had more robust effects
on neurite outgrowth compared with the exosomes from
OGD astrocytes with Ex-Con (p < 0.05, respectively)
(Fig. 5A–D).

Figure 4. MicroRNA 133b (miR-133b)-enriched exosomes
enhance the release of exosomes from primary cultured oxygenand glucose-deprived (OGD) astrocytes. MSC exosomes significantly increased the exosomes released by OGD astrocytes,
and there was no obvious difference on the release from OGD
astrocytes, after treatment with harvested from naive MSCs
(Ex-Naive) and two control exosomes (A). Compared with the
exosome Ex-Naive treatment, exosomes released by OGD astrocytes treated with miR-133b-overexpressing MSCs (Ex-miR133b+) were significantly increased (A) and significantly
decreased (B) by treatment with Ex-miR-133b−, respectively.
Correlated with the miR-133b levels in the multipotent mesenchymal stromal cells (MSCs) (Table 1), the number of exosomes
released by MSCs has no difference between naive MSCs and
the two control MSCs (miR-CON+MSCs and miR-CON−MSCs),
but the exosomal release was significantly increased from the
miR-133b+MSCs and decreased from the miR-133b−MSCs,
compared with that from naive MSCs (B). NivM, naive MSCs;
NivA, naive astrocytes; NON, nontreated OGD astrocytes; MSC,
OGD astrocytes treated with naive MSC exosomes; CON−, miRCON−MSC or OGD astrocytes treated with miR-CON−MSC exosomes; 133b−, miR-133b−MSC or OGD astrocytes treated with
miR-133b−MSC exosomes; CON+, miR-CON+MSC or OGD
astrocytes treated with miR-CON+MSC exosomes; 133b+, miR133b+MSC or OGD astrocytes treated with miR-133b+MSC exosomes. *p < 0.05, mean ± SD, n = 3/group.

miR-133b-Enriched Exosomes Downregulate
the Protein Level of RABEPK
MVBs can either be routed to lysosomes for degradation or to exosomes for secretion65. Lysosomal
dysfunction increases exosomal release66,67; RABEPK,
cooperating with Rab9, participates in the endosome-totrans-Golgi network (TGN) transport, which is essential
for the lysosome formation68. Using Western blot and
immunohistochemistry staining of IBZ tissues, we therefore examined whether the exosomal treatment affects
RABEPK. Our data revealed that ischemia increased
RABEPK protein levels, whereas the Ex-Con treatment
significantly reduced MCAO-increased RABEPK proteins and the Ex-miR-133b+ treatment further decreased
the protein level (p < 0.05, respectively) (Fig. 6A and B).
Double immunofluorescence staining showed the RABEPK
immunoreactivity was largely localized to GFAP+ astrocytes (Fig. 6E–H). We then employed OGD astrocytes to
further examine the effect of MSC exosomes on RABEPK
expression in astrocytes. We found that the Ex-Con treatment significantly reduced RABEPK protein levels in
the astrocytes subjected to OGD, and the Ex-miR-133b+
treatment further lowered the protein level (p < 0.05,
respectively) (Fig. 6C and D).
DISCUSSION
Exosomes released by transplanted cells mediate
the benefits of cell-based therapies for stroke6,8,69,70. It
is therefore reasonable to consider replacing cell-based
therapy for stroke with cell-free exosome-based treatment, which would minimize potential adverse effects of
administering replicating and embolism-forming cells71.
We therefore employed exosomes harvested from naive
MSCs to treat experimental stroke models and found that
the therapeutic effects of exosomes were consistent with
the therapeutic effects of direct MSC treatment7. In the
current study, we extended this exosome therapy concept
to tailor the miRNA content of the exosomes. On the
basis of studies indicating that miR-133b promotes neurovascular plasticity, we generated and employed exosomes enriched with miR-133b for the treatment of rats
subjected to MCAO. We found that miR-133b-enriched
exosomes significantly amplified the therapeutic benefits
for stroke compared to control MSC exosomes. Our in
vivo and in vitro studies also suggest that astrocytes and
possibly other neural parenchymal cells participate in
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Figure 5. Exosomes harvested from oxygen- and glucose-deprived (OGD) astrocytes after treatment with miR-133b-overexpressing
MSCs (Ex-miR-133b+) increase neurite outgrowth. (A) The morphology of cultured neurons in this assay. Exosomes harvested from
OGD astrocytes significantly increased the neurite number and total neurite length per neuron compared with the non-exosometreated primary cultured cortical neurons. The neurite number and total neurite length substantially increased after the neurons were
treated with exosomes harvested from OGD astrocytes that were pretreated by the MSCs infected with blank vector (Ex-Con) and
Ex-miR-133b+, and Ex-miR-133b+-pretreated OGD astrocytic exosomes have the enhanced effect compared with the Ex-Con pretreatment (p < 0.05, respectively; B–D). Con, non-exosome-treated neurons; OGD, neurons treated with exosomes harvested from OGD
astrocytes; Con+, neurons treated with exosomes harvested from OGD astrocytes pretreated with Ex-Con; 133b+, neurons treated with
exosomes harvested from OGD astrocytes pretreated with Ex-miR-133b+. *p < 0.05, mean ± standard deviation (SD), n = 3/group. Scale
bar: 50 µm.

the enhanced functional recovery for stroke induced by
miR-133b-enriched exosomes. miR-133b increased the
secondary release of exosomes from astrocytes, which
appear to more potently enhance neurite outgrowth and
plasticity than naive MSC exosomes. Thus, our study
provides the basis for engineering miRNA content of
exosomes that concurrently regulate multiple molecular
pathways and further promote restorative processes, and
that exosomes, whether naive or engineered, induce secondary release of astrocytic exosomes. Here we focused
on astrocytes, and we do not exclude the possibility that
other parenchymal and inflammatory or vascular cells
may also release secondary exosomes in response to primary exosome stimulation.
EVs, including exosomes, are involved in intercellular
communication within the nervous system54 and play major
roles in neurological diseases and in nerve trauma72,73,
as well as mediate signaling during brain development
and function74. Exosomes released by brain parenchymal

cells modulate neuron–glial–vascular communication and
support neural plasticity33,56,57,75,76. By modulating the interactions between glia and neurons, glial-derived exosomes
promote neurite outgrowth and neuronal survival under
high neuronal activity and/or oxidative stress condition33.
miR-133b-enriched exosomes increased exosome content within the IBZ. This increase may be attributed to
exosomes generated by astrocytes. However, as noted,
we cannot exclude the possibility that the preferential
increase of exosomes released by other neural parenchymal cells induced by miR-133b-enriched exosomes
may also participate in the enhanced neural plasticity and
functional recovery, since other brain parenchymal cells
(e.g., oligodendrocytes) also secrete exosomes that contain
major myelin- and stress-protective proteins, and these
exosomes are involved in glia-mediated trophic support
to axons16.
MVBs are generated by inward budding of the late
endosomal membrane, which gives rise to intraluminal
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Figure 6. MicroRNA 133b (miR-133b)-enriched exosomes downregulate the protein level of Rab9 effector protein with kelch motifs
(RABEPK). Western blot data show that the MSCs infected with blank vector (Ex-Con) treatment significantly downregulated the
RABEPK level increased in the ischemic boundary zone (IBZ) after middle cerebral artery occlusion (MCAO), and miR-133b-overexpressing MSC (Ex-miR-133b+) treatment further reduces the protein level (A, B) (p < 0.05, respectively). Double immunostaining
shows the RABEPK largely expressed in the astrocytes (E–H). Ex-Con treatment significantly reduced the RABEPK level increase
in the astrocytes subjected to oxygen and glucose deprivation (OGD), and Ex-miR-133b+ treatment further reduces the protein level
(C, D) (p < 0.05, respectively). Sham, tissue from sham surgery rats; PBS, MCAO rats treated with phosphate-buffered saline (PBS);
Naive, naive astrocytes; OGD, astrocytes subjected to OGD; CON+, MCAO rats or OGD astrocytes treated with Ex-Con; 133b+,
MCAO rats or OGD astrocytes treated with Ex-miR-133b+. *p < 0.05, mean ± standard deviation (SD), n = 3/group. Scale bar: 50 µm.
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vesicles (ILVs) within late endosomes65. MVBs can be
either routed to lysosomes for degradation or fused with
the plasma membrane to discharge their ILVs as exosomes to the extracellular space. Delivery of lysosomal
enzymes is essential for the maintenance of proper functioning lysosomes, which include addition of a specific
lysosomal tag, mannose 6-phosphate (M6P), to peptides,
for example, lysosomal hydrolases. With binding of these
tags to M6P receptors in the Golgi apparatus and proper
packaging into vesicles destined for the lysosomal system, the hydrolases are released in the acidic environment
of endosomes, and the receptor is retrieved to the Golgi
by retromer and Rab977,78. RABEPK is required for this
endosome-to-TGN transport68, so the lack of RABEPK
may lead to reduced lysosome formation. Lysosomal dysfunction causes increased exosomal release66,67,79,80. Our
data suggest that increased RABEPK level in the IBZ
may consequently increase the lysosome formation.
These data are consistent with prior studies showing
that the autophagy and lysosomal degradation pathways
are stimulated in hypoxia–ischemia-induced brain injury81–85. Endocytosis and autophagy cooperate and share
molecular machinery, such as the Rab GTPase network86–89. The structure of the autophagy pathway, the
autophagosome, can fuse with endocytic structures such
as MVBs to generate the amphisome, which fuses with
the lysosome to degrade the material wrapped inside90–93.
Hypoxia induces exosome release as well13,94. Impacting
the balance between the autophagy and lysosome pathways, by inhibiting the lysosome formation, may increase
the exosome release. The RABEPK expression was
downregulated after miR-133b-enriched exosome treatment in the IBZ may effect on increasing exosomal release
from astrocytes. RABEPK is one of the putative genes
targeted by miR-206 (Targetscan.org), while transforming growth factor-b (TGF-b) inhibits miR-206 levels95.
Although it does not directly target the RABEPK gene,
miR-133b negatively regulates the TGF-b signal pathway
activity96, which may lead to the decrease of RABEPK
expression. Thus, further investigations on the regulation
of miR-133b on miR-206 expression and subsequently on
RABEPK protein level, as well as the balance of lysosome formation and exosome generation, are warranted.
Exosomes penetrate the brain–blood barrier (BBB)97,98;
however, the detailed mechanisms are unclear. Transcytosis in epithelial cells may participate in the process99,100.
Transcytosis allows some materials to enter one side of
a cell and exit from the opposite side. Possibly, in some
circumstances, exosomes in the vessel lumen side may
be endocytosed by the endothelial cell of the BBB to
form as late endosomes/MVBs and then fuse with the
plasma membrane instead of with lysosomes, releasing
the engulfed exosomes, into the brain parenchymal side
extracellular space. We administer the exosomes using an
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IA approach in the current study to reduce potential liver
and lung sequestration. Interestingly, our previous study,
which employed IV administration of naive MSC exosomes7, also showed beneficial effects on the stroke restoration, may suggest that in addition to directly affecting
brain parenchymal cells, administration of exosomes may
also have systemic effects that participate their restorative
effects after stroke. Given that miR-133b-enriched exosomes increase the secondary release of exosomes from
astrocytes, they may also interact with endothelial cells
and increase the exosomes released by endothelial cells.
There are a number of caveats to consider. We have
previously demonstrated that treatment of stroke with
downregulated miR-133b in MSCs significantly reduces
functional recovery after MCAO compared with naive
MSC-treated animals, and treatment with MSCs enriched
in miR-133b significantly enhances functional recovery
compared with naive MSC-treated animals6. Importantly,
our data indicated that the therapeutic effects were mediated by exosome transfer of miR-133b from the MSCs
to the brain. In the present study, our primary goal was
to demonstrate, as a proof of principle, that we can further improve functional recovery by administering tailored exosomes enriched in miR-133b. Further studies,
in which miR-133b exosome content is reduced to verify the function of exosomal miR-133b, are warranted.
Although volumes of cerebral infarction are not altered
by the MSCs and MSC exosome treatment2,7, we cannot exclude the possibility that treatment with exosomes
harvested from miR-133b-overexpressing MSCs at 24 h
poststroke also evokes some neuroprotective benefits in
the ischemic boundary region.
CONCLUSIONS
IA-administered exosomes harvested from miR-133boverexpressing MSCs improve neural plasticity and
functional recovery after stroke beyond that of naive exosomes. Exosomes enriched with mature miR-133b from
miR-133b-overexpressing MSCs further stimulate and
increase exosomes release from astrocytes, possibly by
downregulating the RABEPK expression. The exosomes
derived from OGD astrocytes pretreated with miR-133benriched exosomes promote neurite outgrowth and elongation in vitro. We thus propose that the contribution of
the secondary astrocytic exosome release may contribute
to brain plasticity and subsequent neurological recovery
after stroke.
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